🔴 Xenetic Biosciences is trading 6.48% down in pre-market with no clear catalyst identified

Xenetic Biosciences is trading 6.48% lower at $2.31 in pre-market trading, with no company-specific announcement identified for September 25, 2026.

• Recent disclosures include the proposed all-stock Santersus acquisition and earlier DNase I research updates; neither directly explains the decline.
• The broader market is higher in pre-market trading, so macro sentiment does not clearly account for the move.